A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics of ICP-192 in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs ICP 192 (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors InnoCare Pharma
- 07 Jan 2019 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 New trial record
- 18 Jul 2018 According to an InnoCare Pharma media release, the China Food and Drug Administration has approved Clinical trial application for ICP 192 in solid tumours including gastric cancer.